Altered Associations between Pain Symptoms and Brain Morphometry in the Pain Matrix of HIV-Seropositive Individuals

• Published in: Journal of neuroimmune pharmacology Vol. 13; no. 1; pp. 77 - 89
• Main Authors: Castillo, Deborrah, Ernst, Thomas, Cunningham, Eric, Chang, Linda
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.03.2018; Springer Nature B.V
• Subjects: Biomedical and Life Sciences; Biomedicine; Cell Biology; Immunology; Neurosciences; Original Article; Pain; Pharmacology/Toxicology; Virology; Affective pain; Global health; Brain morphometry; Neuroinflammation; HIV
• DOI: 10.1007/s11481-017-9762-5
• ISSN: 1557-1890

Pain remains highly prevalent in HIV-seropositive (HIV+) patients despite their well-suppressed viremia with combined antiretroviral therapy. Investigating brain abnormalities within the pain matrix, and in relation to pain symptoms, in HIV+ participants may provide objective biomarkers and insights regarding their pain symptoms. We used Patient-Reported Outcome Measurement Information System (PROMIS®) pain questionnaire to evaluate pain symptoms (pain intensity, pain interference and pain behavior), and structural MRI to assess brain morphometry using FreeSurfer (cortical area, cortical thickness and subcortical volumes were evaluated in 12 regions within the pain matrix). Compared to seronegative (SN) controls, HIV+ participants had smaller surface areas in prefrontal pars triangularis (right: p  = 0.04, left: p  = 0.007) and right anterior cingulate cortex ( p  = 0.03) and smaller subcortical regions (thalamus: p  ≤ 0.003 bilaterally; right putamen: p  = 0.01), as well as higher pain scores (pain intensity- p  = 0.005; pain interference- p  = 0.008; pain-behavior- p  = 0.04). Furthermore, higher pain scores were associated with larger cortical areas, thinner cortices and larger subcortical volumes in HIV+ participants; but smaller cortical areas, thicker cortices and smaller subcortical volumes in SN controls (interaction- p  = 0.009 to p  = 0.04). These group differences in the pain-associated brain abnormalities suggest that HIV+ individuals have abnormal pain responses. Since these abnormal pain-associated brain regions belong to the affective component of the pain matrix, affective symptoms may influence pain perception in HIV+ patients and should be treated along with their physical pain symptoms. Lastly, associations of lower pain scores with better physical or mental health scores, regardless of HIV-serostatus ( p  < 0.001), suggest adequate pain treatment would lead to better quality of life in all participants.